Ocugen Inc announces FDA clearance of IND amendment to Initiate OCU400 Phase 3 clinical trial
The Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the other arm with 75 participants that are gene agnostic.